CVS Stock Price Today (July 2026) — CVS Health Corporation Analysis & Key Metrics 2026-07-17
CVS Health Corporation (CVS) is trading at $107.47, up 0.91% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $105.38 (-1.9% upside).
- Volatility remains elevated (16.85% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.10% YoY) alongside significant competitive pressures.
CVS Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
CVS Health Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $198.72B
P/E Ratio
Forward P/E: 12.34
Revenue Growth
Year over Year
Analyst Target
+-1.9% upside potential
Key Investor Questions About CVS
What investors need to know before buying
Based on current market data, CVS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 69.26)
- Fundamentals say: Caution warranted (high leverage concerns)
CVS's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CVS investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $78.35B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, CVS stock traded between $58.50 and $106.15—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 16.85% annualized volatility and β=0.28, the stock exhibits low sensitivity to market moves—making CVS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
What A Patient Holder Is Really Paying For CVS Health Stock
The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.
What's A Strong Quarter Worth When Elevance Health Is Ditching Its Own Markets?
The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.
CVS Health (CVS) Opens Its First Neighborhood Pharmacy In Houston
CVS Health opened its first new pharmacy focused CVS Pharmacy in Houston, introducing a neighborhood format aimed at expanding access to pharmacy care. The company plans to roll out nearly 20 similar locations across the U.S., including additional sites in the Houston area. This move is part of CVS Health's effort to realign its retail footprint and respond to changing consumer preferences for in person pharmacy services. For investors tracking NYSE:CVS, the launch of this new format comes...
CVS Health CEO David Joyner warns private insurers won't cover GLP-1s for weight loss until drug prices drop
Insurance carriers need more proof that paying today’s GLP-1 drug prices will create “enough downstream savings,” assuming that people are healthier long term.
How Much Of Your Portfolio Is Really CVS?
You didn't buy this single stock, but after a powerful run, your favorite ETF might have made a big bet on it for you.
CVS Health (CVS) Stock Looks Pricey On FTC Insulin Settlement
CVS Health stock has climbed sharply over the past year, yet its valuation checks lean expensive. This puts the recent share price strength under closer scrutiny for anyone considering the current upside from here. Over the last 1 year, CVS Health has returned 74.4%, a strong run that raises the bar for what future performance needs to justify at today’s price. Regulatory settlements around pharmacy benefit management and past compliance issues can remove some overhang but also highlight...
How Investors May Respond To CVS (CVS) Dividend Move And GLP‑1 Strategy Across Its Health Platform
Earlier this month, CVS Health’s board approved a quarterly dividend of US$0.665 per share, payable on August 3, 2026, to shareholders of record as of July 23, 2026, while Aetna leadership highlighted the clinical importance of GLP‑1 weight-loss drugs for diabetes and obesity care. Together with improving provider‑payer trust at Aetna and upbeat analyst research, management’s focus on GLP‑1 access and support has reinforced perceptions of CVS Health’s evolving role across insurance,...
UnitedHealth Jumps 10.3% After Raising 2026 EPS Outlook Above Estimates
Stronger medical costs and better-than-expected quarterly profit lifted guidance and boosted confidence in the earnings recovery.
Can Higher Occupancy Offset Lower Admissions in CYH's Q2 Earnings?
Community Health heads into Q2 earnings with mixed operating trends as stronger occupancy meets lower admissions and a smaller hospital portfolio.
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.
Frequently Asked Questions
Common investor questions about CVS Health Corporation
CVS Health Corporation (CVS) is currently trading at $107.47. The RSI (14-day) is at 69.3, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $105.38 implies 1.9% downside from current levels. Volatility is low at 16.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for CVS Health Corporation (CVS): The trailing P/E ratio is 47.14, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 12.34, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.29, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.77. Price-to-Sales is 0.34. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering CVS, the consensus price target is $105.38. This represents a 1.9% downside from the current price of $107.47. The range spans from a low target of $79.00 to a high target of $140.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, CVS Health Corporation (CVS) pays a dividend with a current yield of approximately 2.48%. The annualized dividend rate is $2.66 per share. The payout ratio is 116.7%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-04-23T00:00:00.000Z.
Key risks for CVS Health Corporation (CVS) investors include: 1. Elevated debt levels (D/E ratio of 100.91) which could pressure margins in a rising rate environment. 2. Unsustainable dividend payout ratio (117%) could lead to a dividend cut. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is CVS Health Corporation's (CVS) current debt and financial health profile: Total debt stands at $78.35B. The debt-to-equity ratio is 100.91, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.61. The company holds $11.80B in cash and equivalents. Free cash flow is positive at $5.20B, providing a cushion for debt servicing and shareholder returns.